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Abstract
Background: Tuberculosis is one of the greatest global health concerns and disease management is challenging
particularly in low- and middle-income countries. Despite improvements in addressing this epidemic in Georgia,
tuberculosis remains a significant public health concern due to sub-optimal patient management. Low remuneration
for specialists, limited private-sector interest in provision of infectious disease care and incomplete integration in
primary care are at the core of this problem.
Methods: This protocol sets out the methods of a two-arm cluster randomized control trial which aims to generate
evidence on the effectiveness of a performance-based financing and integrated care intervention on tuberculosis loss
to follow-up and treatment adherence.
The trial will be implemented in health facilities (clusters) under-performing in tuberculosis management. Eligible and
consenting facilities will be randomly assigned to either intervention or control (standard care). Health providers within
intervention sites will form a case management team and be trained in the delivery of integrated tuberculosis care;
performance-related payments based on monthly records of patients adhering to treatment and quality of care
assessments will be disbursed to health providers in these facilities.
The primary outcomes include loss to follow-up among adult pulmonary drug-sensitive and drug-resistant tuberculosis
patients. Secondary outcomes are adherence to treatment among drug-sensitive and drug-resistant tuberculosis patients
and treatment success among drug-sensitive tuberculosis patients. Data on socio-demographic characteristics,
tuberculosis diagnosis and treatment regimen will also be collected. The required sample size to detect a 6%
reduction in loss to follow-up among drug-sensitive tuberculosis patients and a 20% reduction in loss to
follow-up among drug-resistant tuberculosis patients is 948 and 136 patients, respectively.
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Discussion: The trial contributes to a limited body of rigorous evidence and literature on the effectiveness of
supply-side performance-based financing interventions on tuberculosis patient outcomes. Realist and health
economic evaluations will be conducted in parallel with the trial, and associated composite findings will serve
as a resource for the Georgian and wider regional Ministries of Health in relation to future tuberculosis and
wider health policies.
The trial and complementing evaluations are part of Results4TB, a multidisciplinary collaboration engaging
researchers and Georgian policy and practice stakeholders in the design and evaluation of a context-sensitive
tuberculosis management intervention.
Trial registration: ISRCTN, ISRCTN14667607. Registered on 14 January 2019.
Keywords: Tuberculosis, Performance-based financing, Integrated care, Adherence, Loss to follow-up, Cluster
randomized trial
Background
Tuberculosis (TB) is one of the greatest global public
health challenges: in 2017 alone, 10 million people
developed the disease, with over 1.5 million of these
cases resulting in death [1]. While technological and
medical advances are increasingly assisting in disease
detection [2] and treatment [3], TB management still
presents substantial challenges, particularly in low- and
middle-income countries (LMICs) [1]. One of the targets
of the Sustainable Development Goals for 2030 is to end
the global TB epidemic. The 2014 World Health
Organization (WHO) “End TB Strategy” calls for a 90%
reduction in TB deaths and an 80% reduction in TB
incidence over 2015–2030 [4]. Countries must progress
quickly to prevent, detect and treat TB if these targets
are to be achieved.
Country setting
Countries in Eastern Europe and Central Asia face par-
ticularly high burdens of TB, including multidrug-resist-
ant TB (MDR-TB) [1]. Increased drug resistance, low
rates of case detection and treatment adherence, as well
as system-level issues such as funding gaps and limited
integration of TB services across provider types (public
and private, secondary and primary care, and patient com-
munities), all pose critical challenges for TB management
[1]. Contextually sensitive approaches are urgently needed
to address such challenges and improve TB prevention,
detection and treatment.
The current study focuses on Georgia, a country chal-
lenged by a particularly high TB burden. Latest estimates
record TB incidence at 86 (range 72–101) per 100,000
persons, the largest proportion of which (80%) is made
up of patients with pulmonary TB [5]. The majority of
patients with TB is comprised of patients with drug-sus-
ceptible TB (DS-TB; approximately 88.1%) [6]; in 2016,
the estimated prevalence of rifampicin-resistant MDR-
TB (MDR-RR-TB) was 11% among new patients with
TB and 30% among previously treated patients [5].
In line with global averages, overall treatment success
was estimated at 84% for both new and relapsed TB
(2015 estimate). However, the rate fluctuates widely
across regions of Georgia and reporting health facilities:
for DS-TB, treatment success ranges from 46 to 100%
(2015 estimates) [6]; and for MDR-RR-TB, estimates
from 2015 place treatment success at 56% [5].
In both cases, low treatment success is attributed to
weaknesses in patient management [7], which result in
poor patient adherence and patients being lost to follow-
up (LFU) (approximately 30%) [8]. At the core of this
problem is limited provider motivation to provide tuber-
culosis services given the infectious nature of the disease
and low remuneration received by specialists. The latter
additionally presents problems for retaining and attracting
staff towards tuberculosis service delivery. Reducing the
LFU rate is not only essential to ensure improved patient
outcomes, but also to prevent the spread of MDR-TB.
Promising interventions in this regard include integrated
care management and performance-based financing [9].
TB care in Georgia
An extensive overview of the current systems of care for
TB management in Georgia is available online [10]; we
summarize most salient points as follows. TB services in
Georgia are part of general health care services, which
underwent significant reorganization after a recent
privatization. The provision of health care is now based
on a public–private mix, where the government finances
public programmes and health services (e.g. for TB or
diabetes) delivered by private providers. At present, the
government supports universal free access to TB care,
although the financing of TB service provision depends
in part on funding from the Global Fund (GF).
At the outpatient level, TB services are provided at TB
units by TB doctors and TB nurses. There are currently
68 TB units in the country: 58 semi-urban (located in
district centres) and 10 urban TB units. Abkhazia and
South Ossetia are out of control territories and therefore
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the state health programmes are not provided to the
population residing in these territories.
Semi-urban units were recently integrated into district
and regional level Primary Health Care (PHC) centres,
most of which are private. Only a few TB units remain
as separate public institutions, mainly in the capital and
main cities of the country (10 urban centres). The latter
units serve a greater number of patients in total com-
pared to the accumulated number of patients receiving
services in private outpatient units.
Outpatient treatment is provided by TB units located
in urban and semi-urban areas and follows the direct
observation therapy (DOT) strategy. TB units are staffed
by TB doctors and DOT nurses. There is no difference
in service provision at TB units integrated into PHC
(mostly private facilities in semi-urban areas) and in TB
units administratively not integrated into PHC, which
are in most cases public TB facilities in urban areas. In
rural areas, DOT is provided by a general primary care
nurse under the supervision of the TB doctor.
Integrated care management, whereby diverse and
multidisciplinary service providers collaborate to offer
patient-centred services, is an increasingly popular policy
for complex disease management. This is likely to be of
particular value for TB, where management at the primary
care level is based on a variation of the traditional “cascade
of care” approach, whereby a TB specialist works together
with general practitioners, managing the condition in a co-
ordinated and bidirectional manner [11]. In such set-ups,
specialists retain responsibility for clinical management
and treatment oversight, while primary care providers per-
form additional supportive functions. The latter can range
from improving patient follow-up at the PHC level (as in
Norway [12] and Canada [13]) to direct case management
by general practitioners (as in Romania [14], Turkey [15,
16] and India [17]).
Due to various social determinants underlying TB on-
set and the complex needs of patients, successful TB
management requires the input of multiple disciplines.
Several countries, including the United Kingdom and
Norway, have achieved relatively successful TB manage-
ment via multidisciplinary teams (MDTs) which provide
comprehensive and patient-centred care [11]. MDTs
usually consist of professionals with a mix of skills to
meet the needs of patients with TB, especially those with
more complex MDR-TB who require additional psycho-
emotional and clinical support [11].
Each country still has its challenges in fighting TB, yet
international evidence shows that well-designed and inte-
grated models of primary care engagement can improve
treatment access to TB treatment, increase case notification
and improve treatment adherence and success [11]. How-
ever, successful service integration around TB control is
predicated on wider health system factors and performance,
including availability and specialized training of human
resources, managerial competence and interest as relates to
TB service oversight as well as financial viability of service
delivery.
Performance-based financing (or results-based finan-
cing) schemes are interventions where a cash payment
or non-monetary transfer is made conditional upon
attainment and verification of predefined service out-
puts or quality [18]. While prevalent internationally, a
2012 Cochrane review on performance-based finan-
cing (PBF) schemes across low- and middle-income
countries suggested that evidence on the effectiveness
of PBF on health service delivery was weak [19].
Some positive effects on outputs had been shown in
some settings, but the number and quality of evalua-
tions on the topic was poor and PBF is a highly
heterogeneous intervention, and highly context and
implementation dependent [19]. This suggests clear
potential for the proposed clinical trial to add to the
research and evidence base on this topic.
A more recent review of the effectiveness of supply-
side PBF interventions on TB service delivery across
low-, middle- and high-income countries reports similar
findings [20]. Current research suggests that PBF
schemes may impact positively on case detection, service
utilization as well as treatment success. Regarding the lat-
ter, research from Europe (Czech Republic and Romania)
suggests that cure rates may improve by over 20% in set-
tings applying PBF [21]; indeed, patients treated in centres
operating under PBF schemes are found to be at increased
odds of treatment success. However, despite promising
results, the studies appraised are highly heterogeneous and
the evidence base is mixed. Similar to Witter et al.’s [19]
study, RCT evidence is sparse and available studies suggest
that intervention success is highly dependent upon the
scheme design, operationalization and fit to context. Care-
ful calibration of financial incentives to national and
regional contexts is one of the factors affecting PBF scheme
success [20].
Two further issues are of relevance to PBF operationa-
lization, particularly as linked to integrated care manage-
ment [20]:
 Schemes encouraging care coordination show
promise; however, clear links between payments and
desired functions must be drawn. Evidence from
Taiwan suggests that establishing multidisciplinary
teams and assigning overall coordination
responsibilities to one professional cadre may
improve TB management. However, care must be
taken to specify and communicate how rewards are
linked to specific coordination (or other PBF)
functions so as to ensure prompt translation into
clinical practice.
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 PBF schemes and incentives must fit social and
professional norms. Evidence from China suggests
that, if perceived as compromising “professional
dignity” and social norms, financial incentives may
be sabotaged by health care professionals.
Results4TB is a multidisciplinary research project aiming
to engage local Georgian stakeholders in an evidence-based
intervention co-design process prior to rigorous interven-
tion evaluation via randomized trial (this protocol) and
health economic and realist evaluation [22]. Driven by pol-
icy interests, researchers conducted rapid evidence reviews
of performance-based financing interventions and add-
itionally convened two workshops with health care
professionals active in TB care to explore issues affecting
TB service delivery and the cascade of care. Workshops
confirmed that weak remuneration and limited provider
motivation were issues to contend with in the Georgian
contexts; however, further issues contributing to high loss
to follow-up rates were raised, including the lack of
communication between providers and a lack of service
integration. Via repeat contact with policy-makers, and
drawing on previous work by the research team on inte-
grated care, a comprehensive performance-based financing
intervention promoting integrated TB service delivery was
developed and will be evaluated by the research team [9].
This protocol describes the methods of a two-arm clus-
ter randomized control trial that seeks to establish the
effectiveness of the aforementioned intervention against
standard care. The trial is conducted in parallel with a
realist and health economic evaluation, and thus offers a
unique opportunity to study how and why implementa-
tion of care integration and performance-based financing
is operationalized in Georgia while simultaneously study-
ing the cost-effectiveness of such an intervention.
Methods
Aims
This trial aims to determine the effect of an integrated
care and performance-based financing intervention on
loss to follow-up and patient adherence to treatment
among adult patients with pulmonary drug-susceptible
and drug-resistant TB in Georgia.
Objectives
The primary objective of the trial is to compare loss to
follow-up among both drug-susceptible and drug-resist-
ant pulmonary TB patients between intervention and
control arms. Secondary objectives include comparison
of adherence to treatment among patients with pulmon-
ary DS-TB and patients with pulmonary DR-TB in the
two trial arms measured at the end of each completed
treatment month for a patient. Additional secondary
objectives include comparison of treatment success rates
among patients with pulmonary DS-TB in the two trial
arms.
Study design
This is a pragmatic, cluster randomized controlled,
superiority trial with two parallel groups, a fixed number
of clusters of unequal size and a primary outcome of loss
to follow-up among drug-sensitive and drug-resistant
TB outpatients. A clustered design—featuring health
facilities as clusters—was chosen as facilities represent
the ideal frame to disburse performance-related pay-
ments to TB providers. Randomization will be con-
strained and stratified according to the facility operation
type (i.e. integrated vs. specialized care management)
and clusters will be allocated to intervention and control
arms on a 1:1 ratio. Via constrained randomization we
will assure no substantive baseline imbalance exists
among clusters in relation to patient load (values from
2016 and 2017), treatment-related loss to follow-up and
success among drug-susceptible patients (values from
2016), and the number of human resources (doctors and
nurses) and their average salary.
Study setting
This study will be carried out in private and public
health facilities in Georgia meeting the following cluster
(health facility) eligibility criteria. A full list of eligible
facilities is presented in Appendix 1.
Cluster eligibility
To be eligible for the trial, health facilities must comply
with all the following criteria at randomization:
 Facilities must include a TB unit (TB unit at a
specialized TB care facility, or TB unit integrated
into primary health care).
 Facilities must have registered at least 20 patients
with pulmonary DS-TB as treated in the baseline
year used for sampling purposes (2016).
 Facilities must have a pulmonary DS-TB treatment
success rate of 82% or less in the baseline year.
 Facilities must have at least one TB doctor and one
TB nurse available within the facility.
 Managers of health care facility networks, managers
of a single private health care facility providing
general outpatient care or managers of specialized
facilities must consent and agree to participate in
the trial, including agreement to disburse
performance-related payments as set out in the
intervention.
Clusters will be excluded if they are taking part in any
other clinical trials on treatment regimen, new drugs and
adherence to treatment, and/or if outcome monitoring
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frameworks of the facility are assessed as weak (and there-
fore inflexible for intervention) by the National TB
Directory.
We will not exclude clusters in the case of implemen-
tation of interventions that do not fall into the stated
category (e.g. video observed therapy, concomitant
chronic disease care, HIV care, acute disease care).
Patient eligibility
To be eligible for participation in the trial, patients must be:
 Aged 18 years or over
 A new or previously treated patient diagnosed
bacteriologically or clinically with pulmonary TB
(PTB); diagnosis must have been established by a
direct sputum smear microscopy, culture or Gene
Xpert MTB/RIF (bacteriologically confirmed case),
or X-ray, histological or morphological changes
(clinically diagnosed case)
 Assigned to outpatient TB treatment not more than
1 month prior to enrolment in the study; this
restriction (not more than 1 month of treatment)
does not refer to patients whose most recent
treatment outcome was a failure and who were
assigned to a new treatment regimen
 Assigned to outpatient TB treatment at an
outpatient facility or at home (through DOT or
video observed therapy (VOT)) according to the
national TB treatment guidelines.
Patients will be excluded if:
 Diagnosis is extrapulmonary TB
 TB outpatient treatment was started more than 1
month prior to enrolment in the study
 Patients with DS-TB have undergone more than 2
months of hospitalization or patients with DR-TB
have undergone more than 6 months of
hospitalization
 Patients are known at the start of treatment to
require treatment longer than is recommended by
the Georgian TB Management Guidelines for the
appropriate type of TB (Appendix 2)
 Patients are custody patients
 Patients are involved in other clinical studies related
to TB treatment
 Patients are leaving the area within the next 6
months.
Provider eligibility
All facility managers and health care providers offering
TB treatment in eligible facilities are eligible to take part
in this trial.
Comparators
The trial is restricted to two arms: intervention and
control. In the intervention arm, an integrated care and
performance-based financing intervention will be rolled
out and implemented by the Ministry of Labour, Health
and Social Affairs (MoLHSA) of Georgia and the Social
Service Agency across a random group of public and
private health care facilities. Patients presenting at the
said health facilities will be offered the option to enrol
in this study. The control group will comprise health
facilities (i.e. clusters) not implementing the interven-
tion and managing TB as per standard treatment proto-
cols and processes.
Explanation for choice of comparators
While until now no facility or individual-level provider
performance incentive schemes have been implemented
for primary or secondary care services in Georgia (in-
cluding TB and other services), there is now consider-
able interest in performance-based financing schemes
to strengthen the quality of services generally, and TB
care specifically. The intervention under study has been
designed in collaboration with Georgian policy and
practice actors [22], and as such directly reflects
current policy and practice priorities and interests.
Given the limited information on likely intervention
effectiveness, standard care was chosen as the control.
The intervention package includes results-based finan-
cing of health care providers and delivery of integrated
care at the primary care (outpatient level) with the aim
to reduce loss to follow-up among pulmonary DS-TB
and DR-TB patients and to improve TB treatment suc-
cess in patients with pulmonary DS-TB. The intervention
aims to create a better relationship between a patient with
TB and providers by adopting a patient-centred care ap-
proach. The intervention theory of change views this as a
first step in promoting patient engagement in the decision-
making process, thus resulting in improved trust and im-
proved management of co-morbidities and side effects of
TB medication, which in turn contribute to better adher-
ence to treatment. Performance-based payments are made
towards the TB case management team based on quarterly
reports summarizing monthly adherence to treatment
among pulmonary TB patients. The bonus payments to a
TB unit considers the number of patients with TB; cascad-
ing of payment to team members is based on their esti-
mated contribution towards the care process. Payments to
team members have additionally been calibrated against
basic salaries to ensure the relative magnitudes of bonus
payments are appropriate.
Two intervention models are proposed considering the
current set-up of TB services at the outpatient level in
Georgia:
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 Intervention model 1 for TB units
administratively integrated into primary care
facilities
This intervention model applies principally to health
facilities located in semi-urban areas of Georgia. TB
patients which present for care in these intervention
facilities will receive treatment from an integrated,
multidisciplinary team; the care team consists of a
TB doctor, a TB nurse (or a rural nurse for rural
patients) and a family doctor (or a rural doctor for
rural patients); the facility manager is an additional
member of the wider TB service management team.
For these facilities, roles and responsibilities of
health care providers involved in TB case
management have been revised (within the scope
of existing staff competencies) to ensure that
roles align with principles of integrated care
management (see Additional file 1). Staff in the
newly established multidisciplinary team will
additionally receive training on principles of integrated
care, and on managing the side effects of TB treatment
in particular. The latter is targeted at family and TB
doctors.
New tools (a treatment plan for TB patients,
instruments for adherence monitoring, facility
manager guideline on intervention
implementation) complement the revision in roles
and responsibilities and associated trainings.
Bonuses to facilities and staff therein are paid on
a quarterly basis based on monthly adherence
reports and quarterly structured quality of care
assessments (see Additional file 1).
 Intervention model 2 for TB units NOT
administratively integrated into primary care
facilities
This intervention model will be adopted by
facilities which operate specialized TB services;
these facilities are typically free-standing hospitals
and treatment units in urban areas. In the current
model of care for these facilities, TB doctors and
TB nurses are principally involved in care
provision; the facility manager is an additional
member of the wider TB service management
team.
Similar to intervention model 1, the TB doctor and
TB nurse team are expected to deliver integrated
person-centred care. Training on the management of
side effects of TB medications will be provided for TB
doctors and new tools supporting the intervention (a
case management plan, instruments for monitoring, a
facility managers’ guideline on implementing the
intervention) will be introduced. Bonuses to facilities
and staff therein are paid on a quarterly basis based
on monthly adherence reports (see Additional file 1).
In both models, the facility manager plays a vital
role in the delivery of the intervention package. The
manager will be responsible for enabling the work of
the team (such as contracting, creating job descrip-
tions, supervision on the bonus distribution among
the team, etc.) and ensuring a supportive environment
for providing patient-centred care. The total bonus
payment for the facility includes the manager’s and
the institution’s share (the latter potentially covering
some additional costs linked to the intervention, such
as communications). For further details on the inter-
vention, see Additional file 1.
Control
Facilities assigned to the control arm will continue to
provide outpatient care as per standard national TB
management guidelines, and treatment follows DOT
strategies. For patients with DS-TB, flexible DOT is
practised. Patients should visit DOT sites three times
per week, in certain cases twice per week, and take
their drugs for the next day(s) with them. Patients
with DR-TB should present at DOT sites six times
per week (Monday–Saturday). VOT is practised in a
small number of the patients with DR-TB, although
this is likely to expand.
Outpatient treatment is provided by TB units located
in urban and semi-urban areas and staffed by TB doctors
and DOT nurses. DOT in urban areas is provided by
DOT nurses under the supervision of TB doctors. In
practice, in large urban areas, TB nurses and patients
with DS-TB carry out a modified DOT regimen: the
nurse and the patient agree to meet outside the TB unit
three times per week. At this point, the nurse delivers
the medicines to the patient, but no observation of treat-
ment is done.
In rural areas, primary care nurses are assigned to
DOT implementation (for both patients with DR-TB
and those with DS-TB). They undertake DOT under
the supervision of the TB doctor working at the TB
unit at district level but in the same geographic
location.
Allocation
Sixteen units are eligible for participation in the trial.
Clusters will be randomly assigned to either the control
or experimental group with a 1:1 allocation ratio as per
a computer-generated randomization schedule. Units
will be stratified according to the type of intervention to
be implemented (i.e. stratification into specialized vs.
integrated units). Within each stratum, constrained
randomization techniques will be used to allocate a set
number of units to the intervention and control arms:
three specialized and five integrated units will act as
intervention sites; and three specialized and five
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integrated units will act as control sites. In total, eight
units will be allocated to the intervention arm and eight
to the control arm, respectively. Constrained
randomization will be used to generate the allocation
schedule and will be carried out by the research team.
The technique verifies that no baseline imbalances exist
with regards to the following variables: DS-TB and DR-
TB cohort sizes in 2016 and 2017, loss to follow-up and
success rates in 2016; and TB unit ownership type and
number of doctors and nurses and their salaries.
Randomization will only take place after all TB units
give agreement to participate in the study.
Mitigation strategies and actions have been noted in
case of any changes affecting facility clusters during the
study period. If TB units in the control group merge
during the study, the statistical analysis will account for
clustering as appropriate. If a control unit and an inter-
vention unit merge during the study, the intervention
will continue for the merged unit; the principal analysis
will not include these data, but extended analyses will be
run including data as appropriate for time periods pre
merger. If the number of all TB patients decreases below
10 during a quarter, extended statistical analyses will
also account for this trend. Should a national/regional-
level change occur in the salary paid out to health care
providers (a 25% increase or more), recalculation of the
bonus amount will be considered by the intervention
manager in the MoLHSA.
Strategies for improving facility adherence to inter-
vention are foreseen within the intervention itself.
The MoLHSA will support the research team to
develop operational guidelines for facility managers
that will provide guidance on the administration of
the intervention, roles of the staff members, reporting
requirements and so forth. Training will also be pro-
vided to the health personnel and facility managers,
along with practical activities where different possible
scenarios of intervention implementation will be ex-
amined. In addition to this, supervision site visits will
be delivered by the MoLHSA representatives, where
providers will be supported with tips and advice in
intervention sites.
Blinding
Participating units and those administering the inter-
vention will not be blinded. Employees of the partici-
pating units (TB doctors, nurses, family doctors) in
the intervention arm will be trained in the interven-
tion and they will be receiving bonuses. Employees of
the participating units in the control arm will not
receive the training and bonuses, but they will be
aware of the intervention in the intervention arm.
While the intervention will not be promoted among
patients, they might know of the presence or the
absence of the intervention in the TB unit where they
are treated. Once collated, data will undergo a de-
identification process, whereby patient and cluster
identifiers are removed. Statistical analysts will have
access only to this de-identified dataset; for dissemin-
ation of findings, the data will be matched to original
clusters and intervention/non-intervention sites.
The primary outcome is loss to follow-up among
adult drug-sensitive tuberculosis patients. Loss to fol-
low-up is defined as the difference between the two
intervention arms in the proportion of patients who
did not start treatment after diagnosis or whose treat-
ment was interrupted for 2 consecutive months or
more. The outcome will be assessed based on patient
data collected every treatment month.
Secondary outcomes include the following:
 Loss to follow-up among drug-resistant tuberculosis
patients (similarly defined as for drug-sensitive
patients) at each month of a treatment
 Adherence to treatment among drug-sensitive
tuberculosis patients for every month of
treatment. The research team discussed the
adherence definition during a meeting with a
representative from the National Center for
Tuberculosis and Lung Diseases (NCTLD), and
consensus was achieved at the end of this
meeting. The definition draws on local regulations
and relevant evidence in this area [23]. The
definition of adherence to DOT for patients with
pulmonary DS-TB is as follows:
(a) From the start of the treatment to treatment
completion, not more than 1 missing day per
month if the patient visits a facility 8–12 times
during a month to fulfil DOT (DOT is
performed 2 or 3 days per week; every other day,
the patient receives drugs at home)
(b) From the start of the treatment to treatment
completion, no single missing day per month if the
patient visits a facility four times during a month to
fulfil DOT (some patients visit a facility only once a
week for DOT and take drugs for home-taking)
 Adherence to treatment among drug-resistant
tuberculosis patients. Adherence to DOT for
patients with pulmonary DR-TB is defined as not
more than 3 missing days per month (DOT is
performed 26 days per month—6 days a week except
Sunday) from the start of the treatment
 Treatment success among drug-sensitive tuberculosis
patients. Treatment success is defined as per the
WHO [24]. The treatment success rate will be
calculated as the difference in the proportion of
patients classed as successfully treated between trial
arms at 6, 12 and 24months.
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Additional outcomes that we will examine in ancillary
studies include the following:
 Case detection at a primary health care centre
(family doctor level) (via realist evaluation)
 Horizontal coordination between PHC and
specialized TB services (via realist evaluation)
 Costs associated with the management of side
effects caused by TB treatment, and of comorbidities
(via health economic evaluation)
 Outcomes of managing co-morbidities measured by
hospitalization rates due to any severe co-morbid
conditions (like diabetes, cerebrovascular conditions,
etc)
We developed a checklist describing health facility enrol-
ment and allocation, intervention training, rollout, patient
enrolment and assessments according to the Standard
Protocol Items: Recommendations for Interventional Trials
(SPIRIT) guideline (see Fig. 1 and Additional file 2).
Materials and analysis
Sample size
Assuming 15% attrition, we estimated that data for
948 pulmonary DS-TB patients and 136 pulmonary
DR-TB patients must be included in the trial to
detect a 6% reduction in loss to follow-up among DS-
TB patients and a 20% reduction in loss to follow-up
among DR-TB patients. Sample size calculations
assume that all eligible clusters will consent to
participate in the trial; calculations were informed by
historical data (DS-TB data and DR-TB data from
2016) specific to the 16 eligible clusters. Calculations
proceeded in line with recommendations for sample
estimation for cluster randomized control trials in-
cluding a fixed number of clusters of unequal size
[25]. We calculated the sample size corresponding to
80% power and 5% significance, accounting for an
intra-cluster correlation coefficient of 1% and an as-
sumed coefficient of variation in cluster sizes of 20%
(based on average coefficients of variation in actual
cluster sizes according to 2016 data).
Participant recruitment
The study population will consist of all patients with
newly registered or previously treated pulmonary TB
at eligible and consenting TB units between May
2019 and November 2020 with DS and DR pulmonary
TB. All of the eligible patients in the TB units who
offer informed consent to participate in the study will
be enrolled. A screening log will be kept to identify
patients who do and who do not meet the inclusion
criteria. A screening tool (Additional file 3) will be
used for the assessment of the eligibility and the rea-
sons for non-eligibility will be notified. TB doctors
will be responsible for obtaining informed consent
from patients to participate in the study. Patients will
reach the endpoint when they complete the treat-
ment, die or are lost to follow-up. The recruitment
will be stopped by the study coordinators 18 months
after the beginning of the trial only—this is to ensure
that the minimum sample size is achieved and as
much data as possible are collected; the last cohort of
DS-TB patients can thus finalize treatment while still
within the study period.
Data collection
We will collect general patient-level data (demographic,
socio-economic), outcome data (primary, secondary out-
comes) and other TB-related data (diagnosis, referrals)
from participating intervention and control facilities.
The cohort of patients will be followed and respective data
Fig. 1 Health facility enrolment and allocation, intervention training and rollout, and patient enrolment and assessment phases
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collected in different time periods. See Additional file 4
for the data collection tools, timing, data collection tech-
niques, data sources and responsible persons for data
collection.
Various data sources will be used to collect informa-
tion on the cohort of patients enrolled in the trial:
 Facility-level data—number of TB patients treated
by the facility
 Patient-level data:
a. Primary data (individual patient data): TB
doctors will be trained in how to conduct
patient recruitment and additional ethical
procedures. The training will be provided by
the researchers for all TB doctors working in
the intervention and control sites during the
preparatory stage of the study (1 month prior
to the trial initiation). Upon enrolment, TB
doctors will be responsible for collecting
patient socio-demographic data. Data on TB
diagnosis, DOT treatment regimen, adherence
to treatment and referrals will be collected by
a research assistant; the research assistant will
be responsible for data extraction through
document review (TB registries, patient
records). As it is unlikely that facilities will
have timely access to data on TB outcomes
(treatment success in particular), secondary
data will also be consulted
b. Secondary data (cohort data): routine data
sources (national TB database from the
NCTLD, TB registration journals and forms,
and patient records maintained by the TB
units) will be used to extract data on the
aggregate patient cohorts’ outcomes and other
variables including hospitalization of patients
and referrals. Secondary data will be compared
to primary data to evaluate completeness and
accuracy of primary data on adherence;
secondary data will be used to estimate DS-TB
treatment success. A database manager, an
employee of the NCTLD who has access to
the national TB database under his routine
responsibilities, will be contracted under the
study and will be responsible for data
extraction from the national TB database.
Data management and confidentiality
The study results will never present any identified
information, all paper-based data with personal identi-
fiers will be stored in a secure separate place and all
electronic databases will be encrypted and stored in a
password secured computer and on the back-up ser-
ver. Initial and refreshment trainings will be provided
to key study staff on data confidentiality and security.
Data security will be monitored by the project man-
ager on a regular basis.
All study data will be stored at Curatio Inter-
national Foundation (CIF). All electronic and paper-
based data will be kept securely, password-protected
and locked, with limited access only for authorized
persons. All data will be kept on secure drives and
backed up daily to minimize loss of data in the long
term. All study materials including project administra-
tive documents will be stored and then archived in a
locked place.
A metafile for quantitative databases will be created and
stored in the same file as the databases. The metafile will
include information such as sample ID, instrument
settings, list of variables and operator ID. Only authorized
persons will have access to these metafiles.
In accordance with the CIF data management
policy, all data will be stored at the CIF office in a
secure place for an additional 5 years after the project
closure. Paper documents will be destroyed through
shredding. Electronic data will be de-identified and
securely stored on the CIF server.
Auditing
A Data Monitoring Committee (DMC) will be estab-
lished. The DMC is independent of the study organizers.
Members of the DMC will be representatives from the
NCTLD, NCDC and Health Research Union (HRU).
The DMC will meet at least once a year, or more often
as appropriate. During the period of recruitment to the
study, interim analyses will be supplied, in strict confi-
dence, to the DMC, together with any other analyses
that the committee may request. The research funder
(MRC-UK) may audit the trial in order to reassure itself
of the reliability of the data gathered and the ethical
conduct. Audit(s) will be carried out by individual(s)
entirely independent of the trial and the MRC will define
the level of audit required.
Data analysis
A detailed analysis plan will be developed prior to com-
pletion of data collection and locking of the trial data-
base. The analysis plan will include details on the
populations to be included in each analysis, general
principles for analysis (on level of confidence, p values,
adjustment for multiple testing, handling of missing
data), the analytic approach (anticipated to be intention
to treat) as well as analyses for primary and secondary
outcomes (adjusted, unadjusted and wider sensitivity
and subgroup analyses).
Briefly, we anticipate conducting analyses based on
intention-to-treat principles using all complete case
data available. Analyses will be conducted at both
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facility and individual participant levels; for the latter
we will allow for clustering of individuals into facilities.
Unadjusted analyses will examine differences in pri-
mary and secondary outcomes among study groups.
However, we will examine baseline imbalance across
study groups, and in adjusted analyses account for
these in addition to facility weighting (by inverse
variance), study strata and/or covariates used in the
randomization procedures.
We will examine data missingness; if the missing data
rate is more than 5%, we will attempt multiple imput-
ation. Subgroup analyses will be conducted for primary
and secondary outcomes, and will consider the facility
location (urban vs. semi-urban), the private (including
providers with multiple facilities vs. single) or public
health care provider and the patient comorbidity
subgroup (e.g. patients with HIV or diabetes, among
others).
Alternative analyses
While randomized control trials (RCTs) are the gold
standard for evaluating intervention effectiveness, we
acknowledge that effectiveness estimates sourced from
trial analyses may not reflect the full impact of the inter-
vention on the TB population in Georgia; that is, despite
adopting a pragmatic design, the trial is restricted to
evaluating effectiveness among incident cases only and
excludes patients presenting with the most severe forms
of tuberculosis (MDR-TB or those hospitalized for sub-
stantive periods). Effectiveness estimates gleaned may
thus not apply to the entire patient population affected
by the intervention. To address this, a second impact
evaluation study is planned using a controlled inter-
rupted time-series design. The study will focus on the
same outcomes as for the trial, but adopt a wider
perspective and consider outcomes for all patients with
pulmonary TB treated in the units of interest. Similar to
the trial, data will be sourced from the TB reporting sys-
tem; we will include quarterly outcome estimates from
the period 2017–2020 and the first quarter of 2021 (17
data points), and explore the impact of the intervention
on outcomes of interest via segmented regressions. We
hypothesize that the intervention would lead to a lagged
change in TB outcomes and likely affect both the trend
level and gradient over time.
A pre-test of the intervention has been conducted
in two TB units between January and April 2019. The
purpose of the pre-test was to test instruments/tools
and to field-test the intervention. This will also to
help fine-tune monitoring processes. Patients with TB
satisfying the inclusion criteria were enrolled in the
pre-test and followed up for 3 months. Patients re-
cruited during this period will not contribute to the
trial outcomes. The intervention will continue in the
pre-test TB units without interruption.
Time schedule
Please see Additional file 4.
Discussion
Committees
A steering committee will oversee trial management and
implementation; a Data Management Committee will
oversee all issues relating to data collection, quality and
monitoring. Details of these committees are available in
Additional file 5.
Protocol review
The current protocol has been reviewed by the steering
committee of the trial as well as trial funders and the
ethics boards of the institutions involved.
Harms
There are no harms anticipated for either patients or
providers from taking part in the study; post-trial care
procedures are not relevant. It is not anticipated that
interviewing patients about their socio-economic
status will cause any distress except for minimal emo-
tional discomfort. No financial or other types of in-
centives will be provided as a reward for the study
participation (beyond the intervention support itself).
Protocol amendments
Any modifications to the protocol which may impact on
the conduct of the study or potential benefit of the
patient or may affect patient safety, including changes of
study objectives, study design, patient population, sam-
ple sizes, study procedures or significant administrative
aspects, will require a formal amendment to the proto-
col. Such an amendment will be agreed upon by CIF and
Queen Margaret University (QMU) and approved by the
Bioethics Committee at the National Centre for Disease
Control of Georgia and the QMU institutional review
boards, prior to implementation, and notified to the
health authorities in accordance with local regulations.
Administrative changes of the protocol are minor cor-
rections and/or clarifications that have no effect on the
way the study is to be conducted. These administrative
changes will be agreed upon by CIF and QMU and will
be documented in a memorandum. The Bioethics Com-
mittee at the National Centre for Disease Control of
Georgia will be notified of administrative changes at the
discretion of CIF.
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Dissemination of trial results
Trial investigators will communicate results to inter-
national and national academic and policy audiences
internationally via conferences and preparation of
published papers, to national-level policy-makers in
Georgia via policy briefs and stakeholder meetings,
and to lay audiences via lay summary materials (e.g.
posters, videos) to be published on the trial website.
The scientific integrity of the study requires that
results of the trial are adequately shared. Primary out-
come and other study papers, abstracts and presenta-
tion will be developed based on the trial results. Each
product must be shared with and approved by the
Coordinating Center before dissemination.
There are no restrictions on preparation of publica-
tions arising from this trial. All study investigators
will be eligible for authorship, depending on contribu-
tions to the trial, its analysis and manuscript prepar-
ation. The study team will have exclusive use of the
data for 3 years after the project ends. This embargo
period is requested to allow time for additional ana-
lyses and further publication of research findings.
Trial status
 Protocol date and version: 16 May 2019, version 2
 Recruitment start: 24 May 2019
 Recruitment end: 24 November 2020
 WHO Trials dataset items: see Additional file 6
Appendix 1
Table 1 Facilities eligible to take part in the trial
ID Region Urban/semi-urban Facility operation type Facility ownership Facility name
9 Guria Urban Integrated Private Ozurgeti
14 Imereti Urban Specialized Private Kutaisi
16 Imereti Semi-urban Integrated Private Samtredia
29 Kakheti Urban Integrated Private Telavi
32 Kvemo Kartli Semi-urban Integrated Private Gardabani
33 Kvemo Kartli Semi-urban Integrated Private Marneuli
34 Kvemo Kartli Urban Specialized Private Rustavi
38 Mtskheta Mtianeti Semi-urban Integrated Private Dusheti
47 Samegrelo-Zemo Svaneti Semi-urban Integrated Private Khobi
51 Samegrelo-Zemo Svaneti Semi-urban Integrated Public Senaki
52 Samegrelo-Zemo Svaneti Semi-urban Integrated Private Tsalenjikha
53 Samegrelo-Zemo Svaneti Urban Specialized Private Zugdidi
61 Shida Kartli Urban Integrated Private Gori
65 Tbilisi Urban Specialized Public NCTLD
66 Tbilisi Urban Specialized Public TB Unit—# II
67 and 68 Tbilisi Urban Specialized Public Merged TB Units # III and # V
Appendix 2
Table 2 Georgian tuberculosis treatment guidelines: TB
treatment duration by phase and type of patient in Georgia
Type of patient Treatment
duration
(months)
Intensive
phase
duration
(months)
Continuation
phase
duration
(months)
Hospitalization
duration
(months)
DS-TB
DS-PTB 6 2 4 1.5–2*
DS-extra PTB
(TB
meningitis)
12 2 10
DS-extra PTB
(skeletal TB)
9 2 7
DR-TB
MDR-TB/MDR-
RR-TB
individualized
regimen
20–24 > 8 > 12 4–6
MDR-TB/MDR-
RR-TB shorter
regimen
9–12 4–6 5
*It is expected that hospitalization duration will be shortened to 1month for
patients with DS-TB.
DR-TB drug-resistant tuberculosis, DS-TB drug-sensitive tuberculosis, MDR-RR-TB
multidrug-resistant rifampicin-resistant tuberculosis, MDR-TB multidrug-
resistant tuberculosis, PTB pulmonary tuberculosis, TB tuberculosis
Adapted from [26].
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